IQVIA Holdings Inc. $IQV Shares Purchased by Cantillon Capital Management LLC

Cantillon Capital Management LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 27.3% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,926,934 shares of the medical research company’s stock after purchasing an additional 413,256 shares during the period. IQVIA accounts for approximately 2.0% of Cantillon Capital Management LLC’s portfolio, making the stock its 25th biggest position. Cantillon Capital Management LLC’s holdings in IQVIA were worth $366,002,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Asset Dedication LLC boosted its holdings in shares of IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new position in IQVIA during the second quarter valued at $39,000. J.Safra Asset Management Corp grew its position in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the period. Rothschild Investment LLC raised its stake in shares of IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after buying an additional 124 shares during the last quarter. Finally, Root Financial Partners LLC purchased a new position in shares of IQVIA during the 3rd quarter valued at about $43,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.9%

Shares of NYSE:IQV opened at $239.15 on Friday. The business’s 50 day moving average price is $228.82 and its 200-day moving average price is $205.11. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a market capitalization of $40.73 billion, a price-to-earnings ratio of 32.81, a price-to-earnings-growth ratio of 2.46 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the company. Evercore ISI raised their target price on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, January 17th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Truist Financial raised their price target on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.